Screening Adolescents for Type 2 Diabetes Mellitus in a Community Clinic
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the prevalence of Type 2 diabetes or impaired glucose tolerance in a subset of children 10-19 years of age in an inner city community clinic. The demographics of the clinic are 75% African American, 20% Hispanic, 5% other. African American and Hispanic patients have a higher prevalence of diabetes with significant morbidity, predominantly from microvascular and macrovascular disease. Obesity is commonly seen in patients with Type 2 diabetes and contributes to the underlying insulin resistance seen in the disease. Obesity is an increasing health problem among adolescents. Since Type 2 diabetes can be present for several years before diagnosis, it is worrisome that younger children will have undiagnosed Type 2 diabetes for years. This will increase the risk of earlier complications in these patients as young adults.
We hypothesize that the occurrence of abnormal glucose metabolism in 400 children with either a history of obesity, family history of diabetes mellitus, or symptoms suggestive of diabetes mellitus will be higher than the general pediatric population. We believe that a family based educational program can reduce fasting plasma glucose.
| Condition | Intervention |
|---|---|
|
Diabetes Mellitus |
Behavioral: Family based educational program |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Educational/Counseling/Training |
| Official Title: | Screening Adolescents for Type 2 Diabetes Mellitus in a Community Clinic |
| Estimated Enrollment: | 400 |
This is a two part study. The first part is a diabetes screening study of 400 adolescent children who have a risk factor for type 2 diabetes to determine the prevalence of abnormal glucose metabolism in such patients. At the time of glucose screening all children will be given a dietary habit survey and two measures of depression/self-esteem to complete so that we may measure the correlation of depression and obesity and depression and abnormal glucose metabolism.
The second part tests the efficacy of a family based educational program in lowering fasting glucose in children who screen positive for type 2 DM, hyperinsulinemia, or impaired glucose tolerance. This educational assessment will be administered in an observational non-randomized, non-blinded fashion. The dietary habit survey and the measures of self-esteem and depression will aid us in creating this family based educational study.
Eligibility| Ages Eligible for Study: | 10 Years to 19 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria for screening will be patients who have one of the following:
- 120% of ideal body weight or BMI> 27
- Weight greater than 75th percentile
- Family history of type 2 diabetes in first or second degree relative
- Acanthosis nigricans or skin tags as signs of insulin resistance
- Symptoms of hyperglycemia (polyuria, polydipsia, polyphagia, or recurrent infections).
- Symptoms or signs of PCOS (hyperandrogenism, hirsutism, irregular menses)
Contacts and Locations| United States, North Carolina | |
| Duke University | Recruiting |
| Durham, North Carolina, United States, 27710 | |
| Contact: Susan Spratt, MD 919-684-4090 sprat002@mc.duke.edu | |
| Contact: Diana McNeill, MD 919-684-6841 | |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00042042 History of Changes |
| Other Study ID Numbers: | NCRR-M01RR00030-0199 |
| Study First Received: | July 22, 2002 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 21, 2013